Health Care • Biotechnology: Pharmaceutical Preparations
$62.03 ▼ -0.96
(-1.52%)
MKT CAP: $8.76B • VOL: 1.56M
52W L $58 52W H $88
CYTK // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $88.0M | $18.5M | $7.5M |
| YoY Revenue Growth % | +376.6% | +145.3% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$612.3M | -$536.2M | -$496.2M |
| Operating Margin % | -695.4% | -2902.7% | -6589.7% |
| Net Income (GAAP) | -$785.0M | -$589.5M | -$526.2M |
| EBITDA (Normalized) | -$592.4M | -$533.1M | -$495.9M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$510.0M | -$395.9M | -$414.3M |
| Capital Expenditures (CapEx) | $24.8M | $3.9M | $338.9K |
| Free Cash Flow (FCF) | -$534.8M | -$399.8M | -$414.7M |
| FCF Margin % | -607.5% | -2164.1% | -5506.9% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | -13.4% |
| Cash & Short-Term Equivalents | $122.5M | $94.9M | — |
| Total Debt (Short + Long Term) | $246.4M | $93.2M | $1.13B |
| Total Stockholders' Equity | -$659.6M | -$135.4M | $2.32B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CYTK.